ICCM – icecure medical ltd. - ordinary shares (US:NASDAQ)
Stock Stats
News
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues
IceCure Medical Ltd (NASDAQ: ICCM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024
IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences
Form 6-K IceCure Medical Ltd. For: Sep 24
Form 6-K IceCure Medical Ltd. For: Sep 16
Form 6-K IceCure Medical Ltd. For: Sep 12
Form 6-K IceCure Medical Ltd. For: Aug 28
Form 6-K IceCure Medical Ltd. For: Jun 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.